YIYasutaka Inuzuka

Yasutaka Inuzuka

*This is an algorithmically generated author record based on publicly available information.

Yasutaka Inuzuka has a total of 158 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Causes of death in severe aortic stenosis according to symptoms and initial treatment strategies in the TAVR era

    by Ko Yamamoto, Yasuaki Takeji, Tomohiko Taniguchi, Takeshi Morimoto, Shinichi Shirai, Takeshi Kitai, Hiroyuki Tabata, Nobuhisa Ohno, Ryosuke Murai, Kohei Osakada, et al.

    Background: There are no studies evaluating mortality and causes of death in severe aortic stenosis (AS) according to symptoms and treatment strategies in contemporary transcatheter aortic valve replacement era. Methods: Among 3369 consecutive patients with severe AS in the CURRENT AS registry-2, we comprehensively evaluated mortality rates and causes of death in patients with severe AS according to symptoms and treatment strategies. Results: There were 2011 patients with symptomatic severe AS [initial aortic valve replacement (AVR) strategy: N = 1410, and conservative strategy: N = 601] and 1358 patients with asymptomatic severe AS (initial AVR strategy: N = 332, and conservative strategy: N = 1026). During median 2.2 years follow-up, all-cause death occurred in 736 patients, including 297 patients with cardiac death (40.4% of total mortality), 44 patients with vascular death (6.0% of total mortality), and 351 patients with non-cardiovascular death (47.7% of total mortality). In patients with cardiac death, the most common cause was heart failure (22.6% of total mortality), and the second most common cause was sudden death (11.7% of total mortality). In patients with non-cardiovascular death, the most common cause was infection (19.3% of total mortality), and the second most common cause was malignancy (12.2% of total mortality). Cumulative 3-year incidence of all-cause death (proportions of cardiac and non-cardiovascular death) was 22.9% (30.2% and 58.2% of total mortality) in symptomatic severe AS with initial AVR strategy, 53.1% (56.1% and 35.6% of total mortality) in symptomatic severe AS with conservative strategy, 15.5% (23.7% and 68.4% of total mortality) in asymptomatic severe AS with initial AVR strategy, and 24.7% (35.7% and 46.9% of total mortality) in asymptomatic severe AS with conservative strategy. Conclusions: There was a great difference in mortality and causes of death according to symptoms and treatment strategies in severe AS. Non-cardiovascular death was one of the major components of death in patients who were managed not only invasively but also conservatively.

  • Open Access

    Prognostic Implications of Left Ventricular Ejection Fraction Across the Flow‐Gradient Patterns in Severe Aortic Stenosis

    by Tomohiko Taniguchi, Takeshi Morimoto, Yasuaki Takeji, Shinichi Shirai, Kenji Ando, Hiroyuki Tabata, Ko Yamamoto, Ryosuke Murai, Kohei Osakada, Kotaro Takahashi, et al.

    Background: Current guidelines classify normal‐flow low‐gradient (LG) aortic stenosis (AS) with left ventricular ejection fraction (LVEF) ≥50% as “moderate.” However, the prognostic impact of LVEF remains incompletely understood across various hemodynamic subtypes of AS. Methods: We analyzed 3363 consecutive patients with severe AS from the CURRENT AS Registry‐2 (Contemporary Outcomes After Surgery and Medical Treatment in Patients With Severe Aortic Stenosis). Patients were classified into LG AS with normal flow (N=1005), and LG AS with low flow (N=372), and high‐gradient AS (N=1986). Patients were further divided according to baseline LVEF: P P =0.003) with hazards comparable to those with LVEF P =0.59). Conclusions: These findings suggest that LVEF may provide additional prognostic stratification within severe AS phenotypes, particularly in normal‐flow LG AS. Registration: URL: https://center6.umin.ac.jp ; Unique Identifier: UMIN000034169.

  • Stable, Progressive, and Acute Valve Syndrome in Severe Aortic Stenosis: Insights from the CURRENT AS Registry‐2.

    by Tomohiko Taniguchi, Takeshi Morimoto, Yasuaki Takeji, Shinichi Shirai, Kenji Ando, Hiroyuki Tabata, Ko Yamamoto, Ryosuke Murai, Kohei Osakada, Mitsuru Abe, et al.

    Background: A valve syndrome framework (stable valve syndrome [SVS], progressive valve syndrome [PVS], and acute valve syndrome [AVS]) integrates clinical presentation with objective markers, but its prognostic implications remain incompletely characterized. Methods: Among 3369 consecutive patients with severe aortic stenosis (AS) in the CURRENT AS Registry‐2, we analyzed 2824 patients with natriuretic peptide (NP) and left ventricular ejection fraction (LVEF) data. Patients were classified as SVS (no symptoms with low NP), PVS (mild symptoms and/or mildly elevated NP), or AVS (acute deterioration and/or markedly elevated NP or reduced LVEF), and stratified by initial aortic valve replacement (AVR) and conservative strategies. The primary outcome was a composite of death or heart failure hospitalization. Subgroup analyses further classified patients into five phenotypes: SVS, progressive valve signs without symptoms, progressive valve symptoms, acute valve signs without symptoms, and acute valve symptoms. Results: In the initial AVR stratum, AVS was associated with higher risk for the primary outcome compared with SVS (adjusted HR 2.34, 95% CI 1.19–4.59, P=0.01), whereas PVS was not. In the conservative stratum, SVS demonstrated a very low early event rate (1.0% at 6 months), while AVS and PVS had higher risk than SVS. In the five‐phenotype analysis, patients with progressive valve signs without symptoms underwent AVR at rates comparable to SVS yet had worse outcomes than SVS in the conservative stratum (adjusted HR 1.89, 95% CI 1.18‐3.03, P=0.008). Conclusions: A valve syndrome framework highlights limitations of symptom‐based risk stratification and may refine surveillance and intervention strategies in severe AS.

  • Open Access

    Association of Dementia With the Outcome of Patients With Heart Failure: Evidence From the Japanese KCHF Registry

    by Erika Yamamoto, Takao Kato, Takeshi Morimoto, Hidenori Yaku, Yasutaka Inuzuka, Yodo Tamaki, Neiko Ozasa, Yusuke Yoshikawa, Ryoji Taniguchi, Moritake Iguchi, et al.

    Background: Patients with heart failure (HF) have a significantly higher prevalence of cognitive impairment than those without HF. While the association of dementia with prognosis of patients with HF is well documented in Western populations, data from large, prospective cohorts in East Asia, particularly Japan, remain limited. Methods: The KCHF (Kyoto Congestive Heart Failure) registry, a prospective cohort study, enrolled consecutive patients admitted for acute decompensated HF in Japan. We evaluated 3728 patients who were alive at discharge and for whom follow‐up data were available. We compared 1‐year clinical outcomes between patients with and without dementia. Results: Of 3728 participants, 658 (17.6%) were diagnosed with dementia. Patients with dementia were older, more likely to be men, more often had atrial fibrillation and prior stroke with poorer daily life activities and poor adherence to medical therapy, and less often received guideline‐directed medications at discharge than those without dementia. After adjustment for confounders, the excess risk of patients with dementia compared with those without dementia remained significant for all‐cause death and cardiovascular death (hazard ratio [HR], 1.45 [95% CI, 1.17–1.79]; P =0.0007; HR, 1.48 [95% CI, 1.12–1.95]; P =0.006, respectively). However, the excess risk of patients with dementia compared with those without dementia was no longer significant for noncardiovascular death and HF hospitalization (HR, 1.36 [95% CI, 0.96–1.91]; P =0.08; HR, 1.08 [95% CI, 0.88–1.33]; P =0.45, respectively). Conclusions: Dementia in patients with HF is associated with the risk for all‐cause death as well as cardiovascular death.


  • Open Access

    Appetite loss at discharge from acute decompensated heart failure: Observation from KCHF registry

    by Erika Yamamoto, Takao Kato, Hidenori Yaku, Takeshi Morimoto, Yasutaka Inuzuka, Yodo Tamaki, Neiko Ozasa, Yusuke Yoshikawa, Ryoji Taniguchi, Moritake Iguchi, et al.

    Objective: The complex link between nutritional status, protein and lipid synthesis, and immunity plays an important prognostic role in patients with heart failure. However, the association between appetite loss at discharge and long-term outcome remains unclear. Methods: The Kyoto Congestive Heart Failure registry is a prospective cohort study that enrolled consecutive patients hospitalized for acute decompensated heart failure (ADHF) in Japan. We assessed 3528 patients alive at discharge, and for whom appetite and follow-up data were available. We compared one-year clinical outcomes in patients with and without appetite loss at discharge. Results: In the multivariable logistic regression analysis using 19 clinical and laboratory factors with P value < 0.1 by univariate analysis, BMI < 22 kg/m2 (odds ratio (OR): 1.57, 95% confidence interval (CI): 1.11–2.24, P = 0.01), CRP >1.0mg/dL (OR: 1.49, 95%CI: 1.04–2.14, P = 0.03), and presence of edema at discharge (OR: 4.30, 95%CI: 2.99–6.22, P<0.001) were associated with an increased risk of appetite loss at discharge, whereas ambulatory status (OR: 0.57, 95%CI: 0.39–0.83, P = 0.004) and the use of ACE-I/ARB (OR: 0.70, 95% CI: 0.50–0.98, P = 0.04) were related to a decreased risk in the presence of appetite loss. The cumulative 1-year incidence of all-cause death (primary outcome measure) was significantly higher in patients with appetite loss than in those without appetite loss (31.0% vs. 15.0%, P<0.001). The excess adjusted risk of appetite loss relative to no appetite loss remained significant for all-cause death (hazard ratio (HR): 1.63, 95%CI: 1.29–2.07, P<0.001). Conclusions: Loss of appetite at discharge was associated with worse 1-year mortality in patients with ADHF. Appetite is a simple, reliable, and useful subjective marker for risk stratification of patients with ADHF.


  • Open Access

    Admission systolic blood pressure as a prognostic predictor of acute decompensated heart failure: A report from the KCHF registry

    by Yuichi Kawase, Takao Kato, Takeshi Morimoto, Reo Hata, Ryosuke Murai, Takeshi Tada, Harumi Katoh, Kazushige Kadota, Erika Yamamoto, Hidenori Yaku, et al.

    Background: Admission systolic blood pressure has emerged as a predictor of postdischarge outcomes of patients with acute decompensated heart failure; however, its validity in varied clinical conditions of this patient subset is unclear. The aim of this study was to further explore the prognostic value of admission systolic blood pressure in patients with acute decompensated heart failure.Methods: The Kyoto Congestive Heart Failure (KCHF) registry is a prospective, observational, multicenter cohort study enrolling consecutive patients with acute decompensated heart failure from 19 participating hospitals in Japan. Clinical characteristics at baseline and prognosis were examined by the following value range of admission systolic blood pressure: <100, 100–139, and ≥140 mmHg. The primary outcome measure was defined as all-cause death after discharge. Subgroup analyses were done for prior hospitalization for heart failure, hypertension, left ventricular ejection fraction, and medications at discharge. We excluded patients with acute coronary syndrome or insufficient data.Results: We analyzed 3564 patients discharged alive out of 3804 patients hospitalized for acute decompensated heart failure. In the entire cohort, lower admission systolic blood pressure was associated with poor outcomes (1-year cumulative incidence of all-cause death: <100 mmHg, 26.8%; 100–139 mmHg, 20.2%; and ≥140 mmHg, 15.1%, p<0.001). The magnitude of the effect of lower admission systolic blood pressure for postdischarge all-cause death was greater in patients with prior hospitalization for heart failure, heart failure with reduced left ventricular ejection fraction, and β-blocker use at discharge than in those without.Conclusions: Admission systolic blood pressure is useful for postdischarge risk stratification in patients with acute decompensated heart failure. Its magnitude of the effect as a prognostic predictor may differ across clinical conditions of patients.


  • Implantable Cardioverter Defibrillator Therapy in Patients with Acute Decompensated Heart Failure with Reduced Ejection Fraction: An Observation from the KCHF Registry

    by Reo Hata, Takao Kato, Hidenori Yaku, Takeshi Morimoto, Yuichi Kawase, Erika Yamamoto, Yasutaka Inuzuka, Yodo Tamaki, Neiko Ozasa, Yusuke Yoshikawa, et al.


  • Clinical and Prognostic Values of ALBI Score in Patients With Acute Heart Failure

    by Yuya Matsue, Nobuyuki Kagiyama, Tetsuo Yamaguchi, Shunsuke Kuroda, Takahiro Okumura, Keisuke Kida, Atsushi Mizuno, Shogo Oishi, Yasutaka Inuzuka, Eiichi Akiyama, et al.


  • Open Access

    Transcatheter Aortic Valve Implantation vs. Surgical Aortic Valve Replacement for Severe Aortic Stenosis in Real-World Clinical Practice

    by Yasuaki Takeji, Tomohiko Taniguchi, Takeshi Morimoto, Naritatsu Saito, Kenji Ando, Shinichi Shirai, Genichi Sakaguchi, Yoshio Arai, Yasushi Fuku, Yuichi Kawase, et al.

    Background:There are no data comparing transcatheter aortic valve implantation (TAVI) with surgical aortic valve replacement (SAVR) outcomes in real clinical practice in Japan. Methods and Results:We combined 2 independent registries, the K-TAVI Registry (a 6-center prospective registry of consecutive patients who underwent TAVI) and the CURRENT AS Registry (a large, 27-center registry of 3,815 consecutive patients with severe aortic stenosis [AS]). In the K-TAVI Registry, 338 patients underwent TAVI with SAPIEN XT balloon-expandable valves from October 2013 to January 2016, whereas in the CURRENT AS Registry 237 patients with severe AS underwent SAVR from January 2003 to December 2011. Propensity score matching was conducted, with final cohort comprising 306 patients. The cumulative 2-year incidence of all-cause death and heart failure (HF) hospitalization did not differ significantly between the TAVI and SAVR groups (13.7% vs. 12.4% [P=0.81] and 7.9% vs 3.9% [P=0.13], respectively). After adjusting for residual confounders, there were no significant differences between the TAVI and SAVR groups in the risk for all-cause death (hazard ratio [HR] 0.74; 95% confidence interval [CI] 0.35–1.58; P=0.43) or HF hospitalization (HR 1.27; 95% CI 0.40–4.59; P=0.69). Conclusions:These findings from 2 independent Japanese registries suggest that the 2-year risk of all-cause mortality and HF does not differ significantly between TAVI and SAVR groups in real-world practice in Japan.


  • Prognostic Value of BNP Reduction During Hospitalization in Patients With Acute Heart Failure

    by Nobuyuki Kagiyama, Takeshi Kitai, Akihiro Hayashida, Tetsuo Yamaguchi, Takahiro Okumura, Keisuke Kida, Atsushi Mizuno, Shogo Oishi, Yasutaka Inuzuka, Eiichi Akiyama, et al.